Jupiter Topco LLC Takes $575.63 Million Position in Lantheus Holdings, Inc. $LNTH

Jupiter Topco LLC bought a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the second quarter, according to the company in its most recent filing with the SEC. The fund bought 5,188,416 shares of the medical equipment provider’s stock, valued at approximately $575,628,000. Jupiter Topco LLC owned 0.08% of Lantheus as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of the stock. Versor Investments LP purchased a new stake in shares of Lantheus in the fourth quarter valued at $519,000. Reinhart Partners LLC. boosted its stake in shares of Lantheus by 2.2% during the 2nd quarter. Reinhart Partners LLC. now owns 1,599,379 shares of the medical equipment provider’s stock worth $177,437,000 after purchasing an additional 34,501 shares during the period. M&T Bank Corp purchased a new position in shares of Lantheus during the 4th quarter worth about $539,000. Epoch Investment Partners Inc. grew its holdings in Lantheus by 59.4% during the 1st quarter. Epoch Investment Partners Inc. now owns 649,751 shares of the medical equipment provider’s stock valued at $49,284,000 after purchasing an additional 242,222 shares during the last quarter. Finally, First Trust Advisors LP raised its position in Lantheus by 287.6% in the 1st quarter. First Trust Advisors LP now owns 60,258 shares of the medical equipment provider’s stock worth $4,571,000 after purchasing an additional 44,713 shares during the period. Institutional investors own 99.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Citigroup reissued an “outperform” rating on shares of Lantheus in a research note on Friday, May 8th. Mizuho cut their target price on Lantheus from $120.00 to $115.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 29th. Weiss Ratings downgraded Lantheus from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, August 13th. Citizens Jmp reissued a “market outperform” rating and set a $115.00 price target on shares of Lantheus in a research note on Monday, June 29th. Finally, CJS Securities cut Lantheus from a “market outperform” rating to a “market perform” rating in a report on Tuesday, August 4th. Four analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $108.11.

Lantheus Trading Up 0.1%

LNTH stock opened at $100.87 on Wednesday. The company has a market capitalization of $6.58 billion, a PE ratio of 24.36 and a beta of -0.03. Lantheus Holdings, Inc. has a 12 month low of $49.67 and a 12 month high of $111.86. The firm’s 50-day moving average is $103.92 and its 200 day moving average is $91.01. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.06 and a quick ratio of 2.89.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.30 by $0.25. The company had revenue of $388.18 million during the quarter, compared to analysts’ expectations of $363.23 million. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. The firm’s quarterly revenue was up 2.7% on a year-over-year basis. During the same period in the previous year, the company earned $1.57 EPS. On average, research analysts anticipate that Lantheus Holdings, Inc. will post 4.48 EPS for the current year.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.